Rocket Pharma Elects Biopharma Veteran Epstein to Board
Ticker: RCKTW · Form: 8-K · Filed: Dec 5, 2024 · CIK: 1281895
| Field | Detail |
|---|---|
| Company | Rocket Pharmaceuticals, Inc. (RCKTW) |
| Form Type | 8-K |
| Filed Date | Dec 5, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.01 |
| Sentiment | neutral |
Sentiment: neutral
Topics: board-appointment, management
TL;DR
Rocket Pharma adds Novartis ex-CEO David Epstein to its board. Big pharma experience incoming.
AI Summary
Rocket Pharmaceuticals, Inc. announced on December 2, 2024, the election of Dr. David M. Epstein to its Board of Directors. Dr. Epstein brings extensive experience in the biopharmaceutical industry, having previously served as CEO of Novartis Pharmaceuticals. His appointment is expected to enhance the company's strategic direction and operational capabilities.
Why It Matters
The addition of an experienced leader like Dr. Epstein could signal a strategic shift or increased focus on growth and development for Rocket Pharmaceuticals.
Risk Assessment
Risk Level: low — The filing concerns a routine board appointment and does not involve significant financial transactions or operational changes.
Key Players & Entities
- Rocket Pharmaceuticals, Inc. (company) — Registrant
- David M. Epstein (person) — Newly elected Director
- Novartis Pharmaceuticals (company) — Former employer of new director
- Delaware (jurisdiction) — State of incorporation
FAQ
Who was elected to the Board of Directors of Rocket Pharmaceuticals, Inc.?
Dr. David M. Epstein was elected to the Board of Directors of Rocket Pharmaceuticals, Inc.
What is Dr. David M. Epstein's relevant experience?
Dr. Epstein previously served as CEO of Novartis Pharmaceuticals, bringing extensive experience in the biopharmaceutical industry.
When was the earliest event reported in this Form 8-K?
The earliest event reported in this Form 8-K was on December 2, 2024.
What is the principal executive office address for Rocket Pharmaceuticals, Inc.?
The principal executive office address is 9 Cedarbrook Drive, Cranbury, NJ 08512.
What is the SEC file number for Rocket Pharmaceuticals, Inc.?
The SEC file number for Rocket Pharmaceuticals, Inc. is 001-36829.
Filing Stats: 401 words · 2 min read · ~1 pages · Grade level 13.4 · Accepted 2024-12-05 16:14:08
Key Financial Figures
- $0.01 — nge on which registered Common stock, $0.01 par value RCKT The Nasdaq Global Ma
Filing Documents
- ef20039631_8k.htm (8-K) — 24KB
- 0001140361-24-048475.txt ( ) — 154KB
- rckt-20241202.xsd (EX-101.SCH) — 4KB
- rckt-20241202_lab.xml (EX-101.LAB) — 21KB
- rckt-20241202_pre.xml (EX-101.PRE) — 16KB
- ef20039631_8k_htm.xml (XML) — 4KB
02
Item 5.02. Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers; Compensatory Arrangements of Certain Officers. Resignation of General Manager, Commercial Affairs On December 2, 2024, Mark White resigned as General Manager, Commercial Affairs of Rocket Pharmaceuticals, Inc., effective January 1, 2025.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Rocket Pharmaceuticals, Inc. Date: December 5, 2024 By: /s/ Martin Wilson Martin Wilson General Counsel and Chief Corporate Officer, SVP